Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 51427 | 3.855 |
09:34 ET | 8075 | 3.87 |
09:36 ET | 1225 | 3.87 |
09:38 ET | 4790 | 3.855 |
09:39 ET | 2020 | 3.8546 |
09:41 ET | 5391 | 3.845 |
09:43 ET | 6538 | 3.845 |
09:45 ET | 11023 | 3.84 |
09:48 ET | 16679 | 3.85 |
09:50 ET | 10586 | 3.85 |
09:52 ET | 6166 | 3.855 |
09:54 ET | 6219 | 3.85 |
09:56 ET | 8620 | 3.86 |
09:57 ET | 3400 | 3.865 |
09:59 ET | 14393 | 3.86 |
10:01 ET | 5695 | 3.84 |
10:03 ET | 12720 | 3.83 |
10:06 ET | 5074 | 3.84 |
10:08 ET | 5989 | 3.845 |
10:10 ET | 6197 | 3.85 |
10:12 ET | 15085 | 3.835 |
10:14 ET | 824 | 3.8334 |
10:15 ET | 14437 | 3.8208 |
10:17 ET | 5838 | 3.815 |
10:19 ET | 900 | 3.815 |
10:21 ET | 1262 | 3.815 |
10:24 ET | 700 | 3.815 |
10:26 ET | 2631 | 3.815 |
10:28 ET | 14549 | 3.815 |
10:30 ET | 1379 | 3.81 |
10:32 ET | 500 | 3.815 |
10:33 ET | 100 | 3.815 |
10:35 ET | 1153 | 3.81 |
10:37 ET | 10185 | 3.805 |
10:39 ET | 2149 | 3.805 |
10:42 ET | 27489 | 3.81 |
10:44 ET | 295654 | 3.835 |
10:46 ET | 15369 | 3.845 |
10:48 ET | 18324 | 3.805 |
10:50 ET | 2100 | 3.805 |
10:51 ET | 600 | 3.81 |
10:53 ET | 1014 | 3.8072 |
10:55 ET | 17247 | 3.81 |
10:57 ET | 1614 | 3.81 |
11:00 ET | 4100 | 3.805 |
11:02 ET | 2054 | 3.805 |
11:04 ET | 6042 | 3.805 |
11:06 ET | 2015 | 3.8012 |
11:08 ET | 1929 | 3.805 |
11:09 ET | 1000 | 3.8 |
11:11 ET | 7199 | 3.805 |
11:13 ET | 57952 | 3.805 |
11:15 ET | 9716 | 3.805 |
11:18 ET | 8193 | 3.805 |
11:20 ET | 2050 | 3.805 |
11:22 ET | 2000 | 3.805 |
11:24 ET | 7547 | 3.8 |
11:26 ET | 11747 | 3.795 |
11:27 ET | 6489 | 3.795 |
11:29 ET | 69822 | 3.775 |
11:31 ET | 196052 | 3.795 |
11:33 ET | 2007 | 3.8 |
11:36 ET | 17807 | 3.8 |
11:38 ET | 300 | 3.8 |
11:40 ET | 37785 | 3.8 |
11:42 ET | 1988 | 3.795 |
11:44 ET | 6414 | 3.8 |
11:45 ET | 3344 | 3.795 |
11:47 ET | 18757 | 3.795 |
11:49 ET | 16308 | 3.795 |
11:51 ET | 3233 | 3.795 |
11:54 ET | 8631 | 3.795 |
11:56 ET | 4365 | 3.795 |
11:58 ET | 43638 | 3.8 |
12:00 ET | 1786 | 3.8 |
12:02 ET | 1148 | 3.795 |
12:03 ET | 700 | 3.795 |
12:05 ET | 2791 | 3.795 |
12:07 ET | 6851 | 3.795 |
12:09 ET | 1500 | 3.795 |
12:12 ET | 4179 | 3.795 |
12:14 ET | 3950 | 3.795 |
12:16 ET | 16710 | 3.795 |
12:18 ET | 2700 | 3.8 |
12:20 ET | 3298 | 3.795 |
12:21 ET | 6600 | 3.795 |
12:23 ET | 3056 | 3.795 |
12:25 ET | 4463 | 3.795 |
12:27 ET | 3733 | 3.795 |
12:30 ET | 34330 | 3.8 |
12:32 ET | 6027 | 3.8 |
12:34 ET | 5403 | 3.7964 |
12:36 ET | 92426 | 3.815 |
12:38 ET | 14099 | 3.805 |
12:39 ET | 3427 | 3.805 |
12:41 ET | 99105 | 3.805 |
12:43 ET | 29590 | 3.79 |
12:45 ET | 2832 | 3.795 |
12:48 ET | 2200 | 3.795 |
12:50 ET | 3258 | 3.795 |
12:52 ET | 2731 | 3.795 |
12:54 ET | 35280 | 3.795 |
12:56 ET | 2040 | 3.795 |
12:57 ET | 19748 | 3.7783 |
12:59 ET | 17564 | 3.765 |
01:01 ET | 24694 | 3.775 |
01:03 ET | 86048 | 3.79 |
01:06 ET | 201450 | 3.785 |
01:08 ET | 3987 | 3.785 |
01:10 ET | 200 | 3.79 |
01:12 ET | 1577 | 3.79 |
01:14 ET | 21348 | 3.785 |
01:15 ET | 17472 | 3.79 |
01:17 ET | 12850 | 3.785 |
01:19 ET | 11500 | 3.785 |
01:21 ET | 5333 | 3.785 |
01:24 ET | 26010 | 3.7993 |
01:26 ET | 10101 | 3.8 |
01:28 ET | 2200 | 3.8 |
01:30 ET | 700 | 3.795 |
01:32 ET | 1903 | 3.795 |
01:33 ET | 209706 | 3.8 |
01:35 ET | 19242 | 3.795 |
01:37 ET | 225 | 3.7988 |
01:39 ET | 2000 | 3.7997 |
01:42 ET | 7904 | 3.795 |
01:44 ET | 3532 | 3.8 |
01:46 ET | 4155 | 3.8 |
01:48 ET | 2120 | 3.795 |
01:50 ET | 21922 | 3.77 |
01:51 ET | 4238 | 3.775 |
01:53 ET | 3816 | 3.775 |
01:55 ET | 11403 | 3.775 |
01:57 ET | 3232 | 3.77 |
02:00 ET | 8410 | 3.775 |
02:02 ET | 10035 | 3.775 |
02:04 ET | 15647 | 3.775 |
02:06 ET | 6966 | 3.775 |
02:08 ET | 38185 | 3.785 |
02:09 ET | 25044 | 3.76 |
02:11 ET | 18791 | 3.765 |
02:13 ET | 5039 | 3.765 |
02:15 ET | 1742 | 3.76 |
02:18 ET | 4939 | 3.76 |
02:20 ET | 4889 | 3.76 |
02:22 ET | 161014 | 3.7796 |
02:24 ET | 7248 | 3.77 |
02:26 ET | 100 | 3.77 |
02:27 ET | 10150 | 3.76 |
02:29 ET | 4050 | 3.765 |
02:31 ET | 59149 | 3.75 |
02:33 ET | 46330 | 3.76 |
02:36 ET | 170996 | 3.775 |
02:38 ET | 1100 | 3.775 |
02:40 ET | 892 | 3.775 |
02:42 ET | 9927 | 3.76 |
02:44 ET | 1500 | 3.765 |
02:45 ET | 5287 | 3.765 |
02:47 ET | 37196 | 3.775 |
02:49 ET | 43381 | 3.78 |
02:51 ET | 800 | 3.79 |
02:54 ET | 4417 | 3.785 |
02:56 ET | 11440 | 3.775 |
02:58 ET | 4677 | 3.775 |
03:00 ET | 22036 | 3.765 |
03:02 ET | 2434 | 3.76 |
03:03 ET | 8276 | 3.765 |
03:05 ET | 2440 | 3.765 |
03:07 ET | 14785 | 3.75 |
03:09 ET | 2500 | 3.75 |
03:12 ET | 3109 | 3.75 |
03:14 ET | 77799 | 3.74 |
03:16 ET | 5805 | 3.74 |
03:18 ET | 4400 | 3.74 |
03:20 ET | 12092 | 3.74 |
03:21 ET | 38801 | 3.73 |
03:23 ET | 4448 | 3.73 |
03:25 ET | 9463 | 3.73 |
03:27 ET | 10100 | 3.73 |
03:30 ET | 17500 | 3.735 |
03:32 ET | 19903 | 3.72 |
03:34 ET | 8104 | 3.725 |
03:36 ET | 68094 | 3.735 |
03:38 ET | 1900 | 3.735 |
03:39 ET | 31377 | 3.75 |
03:41 ET | 61522 | 3.75 |
03:43 ET | 10030 | 3.745 |
03:45 ET | 14985 | 3.745 |
03:48 ET | 25117 | 3.74 |
03:50 ET | 26714 | 3.735 |
03:52 ET | 127466 | 3.745 |
03:54 ET | 13667 | 3.745 |
03:56 ET | 49078 | 3.745 |
03:57 ET | 137177 | 3.735 |
03:59 ET | 153384 | 3.74 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.3B | -10.8x | --- |
Vera Therapeutics Inc | 2.2B | -20.0x | --- |
Dyne Therapeutics Inc | 2.3B | -6.7x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.1x | --- |
Avidity Biosciences Inc | 2.5B | -8.8x | --- |
Keros Therapeutics Inc | 2.0B | -10.5x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.8x |
Price/Sales (TTM) | 4,334.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.